Regeneron Pharmaceuticals Inc. buy WatchMen
Start price
25.01.21
/
0%
€463.95
Target price
25.01.22
€500.00
Performance (%)
15.42%
End price
26.01.22
€535.50
Summary
This prediction ended on 26.01.22 with a price of €535.50. The BUY prediction by WatchMen finished with a performance of 15.42%. This prediction was marked as speculative and is excluded from WatchMen's performance statistics.Regeneron Pharmaceuticals, Inc. is a biotechnology company that is engaged in the discovery, development, and commercialization of medicines for the treatment of serious medical conditions. The company's products include EYLEA, a treatment for wet age-related macular degeneration and diabetic macular edema; Dupixent, a treatment for atopic dermatitis and asthma; and Libtayo, a treatment for certain types of cancer. Regeneron also has a strong focus on research and development, with a pipeline of potential new treatments for a variety of diseases. The company is headquartered in Tarrytown, New York and trades on the NASDAQ stock exchange under the symbol REGN.
Performance without dividends (%)
| Name | 1w | 1m | 1y | 3y |
|---|---|---|---|---|
| Regeneron Pharmaceuticals Inc. | -1.902% | -1.902% | 17.050% | 99.083% |
| iShares Core DAX® | 2.594% | -1.158% | 14.782% | 16.813% |
| iShares Nasdaq 100 | 3.553% | -1.727% | 43.265% | 44.227% |
| iShares Nikkei 225® | 0.687% | -8.354% | 18.454% | 1.361% |
| iShares S&P 500 | 2.209% | -0.942% | 31.361% | 42.812% |
According to WatchMen what are the pros and cons of Regeneron Pharmaceuticals Inc. for the foreseeable future?
Pros
Could be worthwhile Investment >10% per year
Revenue growth >5% per year expected
EBIT growth >5% per year expected
Higher EBIT margin than peer group
Fair valuation
High dividend yield expected
positive Cash Flow expected
Good rating
Standard Investments for future growth
Valuable balance sheet
Normal challenges to pay loans and raise capital
ROE higher than 10% per year
Capable Management
Good culture
Innovative
Differentiated customer and product portfolio
Growths faster than the competition
Stable Large shareholder and/or long term investor
Medium risks for its business
Some uniques
Sustainability is important
Top 10 in its market
Small cyclical dependencies
Known brand
Future proof or reliable business model
Cons
Comments by WatchMen for this prediction
In the thread Regeneron Pharmaceuticals Inc. diskutieren
Buy Regeneron Pharmaceuticals Inc.
Kursziel gesetzt auf 500,0
In the thread Trading Regeneron Pharmaceuticals Inc.
Die von WatchMen gewählte maximale Laufzeit wurde überschritten